WorldCat Linked Data Explorer

Turtle N-Triple JSON-LD RDF/XML HTML Contact Us Home

http://worldcat.org/entity/work/id/1066169423

Targets and emerging therapies for schizophrenia

BNew and emerging directions in pharmaceutical research to better treat schizophrenia/b/ Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. iTargets and Emerging Therapies for Schizophrenia/i presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. iTargets and Emerging Therapies for Schizophrenia/i:ulliProvides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment/liliDraws from chemistry, biology, and pharmacology for more effective drug targeting and discovery/liliExplores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides/li/ul With iTargets and Emerging Therapies for Schizophrenia/i as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.

Open All Close All

type

about

author

contributor

creator

description

http://schema.org/description

  • "BNew and emerging directions in pharmaceutical research to better treat schizophrenia/b/ Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. iTargets and Emerging Therapies for Schizophrenia/i presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. iTargets and Emerging Therapies for Schizophrenia/i:ulliProvides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment/liliDraws from chemistry, biology, and pharmacology for more effective drug targeting and discovery/liliExplores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides/li/ul With iTargets and Emerging Therapies for Schizophrenia/i as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality."@en
  • "Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Jeffrey Albert and Michael Wood present the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined."

editor

genre

http://schema.org/genre

  • "Electronic books"@en
  • "Electronic books"

name

http://schema.org/name

  • "Targets and Emerging Therapies for Schizophrenia"
  • "Targets and emerging therapies for schizophrenia basics, approaches, and advances"
  • "Targets and emerging therapies for schizophrenia"@en
  • "Targets and emerging therapies for schizophrenia"

workExample